Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DES Clear all
Completed Not applicable Interventional

Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)

NCT00781573
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Clopidogrel
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Sep 26, 2026, 1:12 AM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT02389946
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease, Acute Coronary Syndrome, Angina Pectoris
Interventions
Orsiro DES, Xience DES
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
55
States / cities
Fairhope, Alabama • Concord, California • La Mesa, California + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 26, 2026, 1:12 AM EDT
Completed Not applicable Interventional Results available

XIENCE 28 USA Study

NCT03815175
View directory record Official record
Conditions
Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions
XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 26, 2026, 1:12 AM EDT
Completed Phase 3 Interventional Results available

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

NCT01510327
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loveland, Colorado • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 26, 2026, 1:12 AM EDT
Completed Not applicable Interventional Results available

Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels

NCT02098876
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Integrity Zotarolimus eluting stent, Xience Xpedition everolimus eluting stent, Optical Coherence Tomography (OCT), Intravascular Ultrasound (IVUS)
Device
Lead sponsor
Emory University
Other
Eligibility
30 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Sep 26, 2026, 1:12 AM EDT
Completed Phase 3 Interventional

Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)

NCT00165035
View directory record Official record
Conditions
Coronary Disease
Interventions
CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
1,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Sep 26, 2026, 1:12 AM EDT
Active, not recruiting Not applicable Interventional

SELUTION 4 De Novo Small Vessel IDE Trial

NCT05946629
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES
Device
Lead sponsor
M.A. Med Alliance S.A.
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
65
States / cities
Jonesboro, Arkansas • Chula Vista, California • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 26, 2026, 1:12 AM EDT
Completed Phase 2Phase 3 Interventional

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

NCT02597803
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Sep 26, 2026, 1:12 AM EDT
Completed No phase listed Observational

VQI DELTA Paclitaxel Device Safety Analysis

NCT04110288
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Paclitaxel, Non-drug coated Device Treatment
Drug · Device
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
219,483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 26, 2026, 1:12 AM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

NCT00823212
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 26, 2026, 1:12 AM EDT
Completed No phase listed Observational Results available

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT04175626
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease, Acute Coronary Syndrome, Angina Pectoris
Interventions
Orsiro DES
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
33
States / cities
Fairhope, Alabama • Concord, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 26, 2026, 1:12 AM EDT
Completed No phase listed Observational

Mechanisms of Emotion Regulation Underlying Successful CBT in Depression

NCT04328103
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavior Therapy (CBT), Nonspecific Supportive Therapy (PBO)
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 26, 2026, 1:12 AM EDT
Completed Phase 1 Interventional

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

NCT02240407
View directory record Official record
Conditions
Pompe Disease
Interventions
Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, Rapamycin, saline, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream
Genetic · Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 26, 2026, 1:12 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

@neurIST : Intregrated Biomedical Informatics for the Management of Cerebral Aneurysms

NCT05526352
View directory record Official record
Conditions
Intracranial Aneurysm
Interventions
Not listed
Lead sponsor
University Hospital, Geneva
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2040
U.S. locations
3
States / cities
San Francisco, California • Cincinnati, Ohio • Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 26, 2026, 1:12 AM EDT
Completed No phase listed Observational

Xience V at Wake Forest University Baptist Medical Center (WFUBMC)

NCT00937573
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Stents
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 26, 2026, 1:12 AM EDT
Completed No phase listed Observational

An Observational Registry Using Drug Eluting Stents (DES) in Patients in a Real-World Setting (DEScover Registry).

NCT00489320
View directory record Official record
Conditions
Cardiovascular Diseases, Vascular Disease, Arterial Occlusive Disease, Arteriosclerosis, Atherosclerosis
Interventions
Cypher Stent
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
Not listed
Enrollment
7,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 1, 2007 · Synced Sep 26, 2026, 1:12 AM EDT
Completed Phase 3 Interventional Results available

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

NCT02974907
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 26, 2026, 1:12 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

NCT00699751
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer, Bone Metastases
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Best standard of care (BSoC)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
7
States / cities
Los Angeles, California • Roseville, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 26, 2026, 1:12 AM EDT
Terminated Not applicable Interventional

OPTIMIZE IDE for the Treatment of ACS

NCT03190473
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
DES
Device
Lead sponsor
Svelte Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Fairhope, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 26, 2026, 1:12 AM EDT
Withdrawn No phase listed Observational

REWARDS- In-stent Restenosis

NCT03008772
View directory record Official record
Conditions
In-Stent Coronary Artery Restenosis
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 26, 2026, 1:12 AM EDT
Not listed Not applicable Interventional

Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection

NCT03427346
View directory record Official record
Conditions
Barrett Esophagus, Barrett Adenocarcinoma, Esophagus Neoplasm
Interventions
Endoscopic mucosal resection, Endoscopic submucosal dissection
Procedure
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Other
Eligibility
18 Years to 99 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 26, 2026, 1:12 AM EDT
Completed Phase 4 Interventional Results available

PROMUS Element Plus US Post-Approval Study

NCT01589978
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
2,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
52
States / cities
Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 26, 2026, 1:12 AM EDT
Not listed Phase 3 Interventional Results available

SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries

NCT00114972
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent, Coronary Artery Bypass Surgery
Device · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
21 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
32
States / cities
Sacramento, California • Washington D.C., District of Columbia • Atlantis, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Sep 26, 2026, 1:12 AM EDT
Completed Phase 4 Interventional Results available

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty

NCT01121224
View directory record Official record
Conditions
Saphenous Vein Graft Atherosclerosis
Interventions
Bare Metal Stent, Drug-Eluting Stent, Blinded clopidogrel, Placebo, Thienopyridine (open-label)
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
25
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 26, 2026, 1:12 AM EDT